Deosen Biochemical Ltd.

Deosen Biochemical Ltd. is a manufacturer specializing in biopolymer products, including xanthan gum and welan gum, catering to diverse industries such as food, pharmaceuticals, and personal care. Founded in 1992 in Zibo, China, Deosen Biochemical Ltd. focuses on producing biopolymers.

The company has undergone strategic pivots but has consistently remained dedicated to the biochemical sector. Under the leadership of CEO Jing Wang, Deosen has expanded its operations globally. The company has successfully secured funding, with a latest round of funding being a Buyout worth USD 181. 00 mn from Warburg Pincus, bringing the total amount raised to USD 181.

00 mn through four deals. Deosen Biochemical (Ordos) Ltd. specializes in the production and supply of xanthan gum, welan gum, and DSTA gum, focusing on high-quality products for various industries. Their flagship xanthan gum products, marketed under the Ziboxan® and Zibozan® brands, serve as effective thickening agents, stabilizers, and emulsifiers, widely utilized in food applications, personal care, cosmetics, pharmaceuticals, industrial processes, and oilfield drilling.

The company’s primary markets include over 70 countries, serving diverse clients from food manufacturers to pharmaceutical firms and oil drilling contractors. Deosen Biochemical operates a B2B business model, supplying products directly to manufacturers instead of retailing to end consumers. The company typically engages in bulk orders of products such as Ziboxan® xanthan gum, negotiating contracts based on specific volume requirements. Their pricing structure is competitive for large-scale orders, delivering cost efficiencies across multiple sectors.

The company's reputation for high-quality, environmentally friendly products supports its revenue generation, although specific revenue figures are not disclosed. Deosen Biochemical plans to enhance its product offerings with new formulations of xanthan and welan gum, targeting a launch within the next year. The company aims to expand into emerging markets in Southeast Asia and South America by 2025, utilizing recent funding to bolster production capabilities and enhance distribution networks. Following the exit of Warburg Pincus and Milestone Capital Management, Deosen is positioned to strategically reinvest in growth initiatives.